$1.64 Earnings Per Share Expected for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) This Quarter

Equities analysts forecast that Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) will announce earnings of $1.64 per share for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Zimmer Biomet’s earnings, with estimates ranging from $1.58 to $1.68. Zimmer Biomet reported earnings of $1.90 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 13.7%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Zimmer Biomet will report full-year earnings of $6.73 per share for the current financial year, with EPS estimates ranging from $6.67 to $6.77. For the next fiscal year, analysts anticipate that the company will post earnings of $7.09 per share, with EPS estimates ranging from $6.78 to $7.31. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Zimmer Biomet.

Zimmer Biomet (NYSE:ZBHGet Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.21. Zimmer Biomet had a net margin of 2.85% and a return on equity of 12.23%. The business had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter last year, the company posted $1.71 earnings per share. The business’s quarterly revenue was up 3.9% on a year-over-year basis.

Several research analysts recently issued reports on ZBH shares. Piper Sandler reduced their target price on shares of Zimmer Biomet from $135.00 to $110.00 in a report on Monday, February 7th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Zimmer Biomet from $140.00 to $121.00 and set a “hold” rating for the company in a report on Tuesday, February 8th. Canaccord Genuity Group lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating and dropped their price target for the company from $165.00 to $125.00 in a research report on Tuesday, February 8th. Citigroup dropped their price target on shares of Zimmer Biomet from $135.00 to $125.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Zimmer Biomet from $150.00 to $114.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 8th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $140.65.

Shares of Zimmer Biomet stock traded up $0.70 during trading on Friday, hitting $117.61. 845,406 shares of the company’s stock were exchanged, compared to its average volume of 1,415,815. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.89 and a current ratio of 1.69. The business has a 50-day simple moving average of $123.32 and a 200-day simple moving average of $124.33. Zimmer Biomet has a 52-week low of $108.47 and a 52-week high of $169.98. The stock has a market capitalization of $24.65 billion, a price-to-earnings ratio of 114.19, a PEG ratio of 2.82 and a beta of 1.16.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Monday, June 27th will be given a dividend of $0.24 per share. The ex-dividend date is Friday, June 24th. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. Zimmer Biomet’s payout ratio is presently 93.20%.

In related news, VP Chad F. Phipps sold 35,149 shares of the business’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $121.97, for a total transaction of $4,287,123.53. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.73% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Zimmer Biomet by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after acquiring an additional 3,695,510 shares during the period. BlackRock Inc. raised its stake in shares of Zimmer Biomet by 0.9% in the 4th quarter. BlackRock Inc. now owns 21,761,864 shares of the medical equipment provider’s stock valued at $2,764,628,000 after acquiring an additional 196,353 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Zimmer Biomet by 11.5% in the 1st quarter. JPMorgan Chase & Co. now owns 12,772,584 shares of the medical equipment provider’s stock valued at $1,633,612,000 after acquiring an additional 1,321,955 shares during the period. State Street Corp raised its stake in shares of Zimmer Biomet by 3.3% in the 4th quarter. State Street Corp now owns 9,029,019 shares of the medical equipment provider’s stock valued at $1,149,182,000 after acquiring an additional 290,402 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of Zimmer Biomet by 4.9% in the 1st quarter. American Century Companies Inc. now owns 5,837,756 shares of the medical equipment provider’s stock valued at $746,649,000 after acquiring an additional 272,469 shares during the period. 90.34% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile (Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Featured Stories

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.